After Hiccups, Astellas’s Mirabegron On Course For Indian Debut?
Astellas’s overactive bladder drug mirabegron, which previously failed to pass muster in India, has now been cleared by an expert panel in the country, though competition appears to be building up alongside.
You may also be interested in...
Astellas's new mid-term business plan envisages mid-single-digit sales growth for the company over the next two years, with new products in oncology and urology the main drivers of the expected increase and further acquisitions seemingly on the cards. The firm has also just set up a new U.S. joint venture to pursue R&D in new therapeutic areas.
A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.
Eli Lilly responds with baricitinib donation plan and efforts to sew up royalty free voluntary licenses with local Indian firms as challenger Natco seeks a compulsory license for its version of the JAK inhibitor, which it is ready to launch.